Highlights Indivior PLC Nasdaq

Equities

INDV

GB00BN4HT335

Market Closed - Nasdaq Other stock markets 21:00:00 18/06/2024 BST			5-day change	1st Jan Change
15.86 ^USD	-2.94%		-5.99%	+3.86%

06-18	Indivior PLC Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (Ovee 2.7Mg) and In Naloxone (4 Mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression on Respiratory Depression	CI
06-10	Indivior PLC Announces Dosing of First Subject with Indv-2000 in A Phase 2 Study Assessing the Safety and Efficacy of Indv-2000 in Individuals with Opioid Use Disorder	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Indivior PLC Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (Ovee 2.7Mg) and In Naloxone (4 Mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression on Respiratory Depression	06-18	CI
Indivior PLC Announces Dosing of First Subject with Indv-2000 in A Phase 2 Study Assessing the Safety and Efficacy of Indv-2000 in Individuals with Opioid Use Disorder	06-10	CI
Indivior Confirms FY24 Outlook	05-23	MT
Indivior reconfirms 2024 outlook amid NY-listing decision	05-23	AN
Indivior plc Reaffirms Revenue Guidance for the Year 2024	05-23	CI
London-listed Indivior Confirms Plan for Primary Listing in US	04-25	MT
UK-listed drugmaker Indivior seeks shareholder nod for US listing	04-25	RE
Indivior shares down despite profit boost on planned shift to New York	04-25	AN
Indivior Reports Higher Q1 Net Income, Net Revenue	04-25	MT
Tranche Update on Indivior PLC's Equity Buyback Plan announced on November 17, 2023.	04-25	CI
Indivior plc Reconfirms Earnings Guidance for 2024	04-25	CI
Indivior PLC Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
C4X Discovery seeks AIM delisting but half-year revenue skyrockets	03-27	AN
Indivior PLC Announces Publication Demonstrating that OPVEE® Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone	03-11	CI
Indivior chief commercial officer sells GBP500,000 in shares	03-08	AN
Oxford Nanopore Technologies top team buys shares	03-07	AN
Indivior says US court draws line on multi-district Suboxone case	02-29	AN
Indivior Unit Obtains Final Settlement Approval Over Antitrust Multidistrict Litigation	02-29	MT
Global markets live: Booking, Diageo, AT&T, Nvidia, UBS...	02-23
Health Care Up After Moderna Earnings -- Health Care Roundup	02-22	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Indivior PLC Nasdaq

Equities

INDV

GB00BN4HT335

Highlights

Filters